Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,960
datasets available to search
ShareScore release 0.9.0
Dataset results
3,960 results for “lung patient”
MicroRNA profiling data of fresh lung adenocarcinoma and adjacent normal tissues obtained from ten Korean patients using next-generation sequencing
GEO Series GSE196633. Homo sapiens. 20 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Integrative single-cell RNA and T-cell receptor analyses reveal transcriptional features of antigen-reactive tumor-infiltrating regulatory T cells in patients with lung cancer
GEO Series GSE164146. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing; Other.
Inhibition of TGFβRI as a therapy for GATA4 deficient lung cancers [patient samples]
GEO Series GSE84852. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Identification of target genes in human lung tissue of COPD patients
GEO Series GSE106986. Homo sapiens. 19 samples. Type: Expression profiling by array.
Gene and miRNA expression profiling of primary cell cultures of lung fibroblasts obtained from cancer or normal tissue of lung cancer patients
GEO Series GSE97545. Homo sapiens. 60 samples. Type: Non-coding RNA profiling by array.
Spatial transcriptomic profiling of the lung tissues from a patient with recurrent anti-synthetase syndrome associated interstitial lung disease after bilateral lung transplantation and one untreated
GEO Series GSE286227. Homo sapiens. 2 samples. Type: Other.
Pre-clinical proof-of-concept of anti-fibrotic activity of caveolin-1 scaffolding domain peptide LTI-03 in ex vivo precision cut lung slices from patients with Idiopathic Pulmonary Fibrosis
GEO Series GSE305464. Homo sapiens. 94 samples. Type: Expression profiling by high throughput sequencing.
Peripheral profiles from patients with cancerous and non cancerous lung diseases
GEO Series GSE24709. Homo sapiens. 71 samples. Type: Non-coding RNA profiling by array.
Lung Adenocarcinoma derived from Normal Bronchial Epithelial Cells Co-cultured with HPV-Positive Peripheral Blood lymphocyte from Lung Cancer Patient
GEO Series GSE38949. Homo sapiens. 3 samples. Type: Expression profiling by RT-PCR.
Transcriptome of tumor biopsy sample of patient with non-small-cell lung adenocarcinoma, ALK rearrangement positive
GEO Series GSE133605. Homo sapiens. 1 samples. Type: Expression profiling by array; Third-party reanalysis.
Dataset related to article "Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience."
<p><strong>Aim:</strong> Immunotherapy opened new frontiers in metastatic non-small-cell lung cancer treatment, but not all patients benefit from it. <strong>Methods:</strong> We retrospectively evaluated 65 metastatic non-small-cell lung cancer patients, treated with nivolumab, considering as disadvantaged subgroups those with poor performance status, elderly, patients with brain metastases at baseline, with high disease burden and refractory to platinum. <strong>Results:</strong> No differences in overall survival or time to treatment failure were found according to performance status, age, presence of brain metastases at baseline or high disease burden. Conversely, patients refractory to platinum had a statistically significant shorter overall survival and time to treatment failure. At multivariate analysis only platinum resistance was confirmed as an independent predictive factor. <strong>Conclusion:</strong> Our study suggests that only refractoriness to platinum salts influence the efficacy of nivolumab.</p>
Dataset related to article "Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer."
<p>PURPOSE:</p> <p>To evaluate the clinical-pathological and prognostic significance of the circulating PD-L1 level in patients with surgically treated NSCLC, by combining data for PD-L1 expression with other immune-related markers and tumor metabolism.</p> <p>METHODS:</p> <p>Overall, 40 patients with resected NSCLC (stage Ia-IIIa) who had preoperative blood storage and underwent staging PET/CT were enrolled for the study. In all cases, we determined plasma levels of PD-L1 (pg/ml), immune-reactive areas (IRA %) covered by CD3, CD68, CD20, CD8, PD-1, and PD-L1 in the tumor specimen, and metabolic parameters on PET, i.e., SUV<sub>max</sub>, SUV<sub>peak</sub>, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Variables were statistically analyzed to establish their association with disease-free survival (DFS).</p> <p>RESULTS:</p> <p>The circulating levels of PD-L1 in the bloodstream could be determined in 38/40 (95%) samples. The mean and median expression levels were 34.86 pg/ml and 24.83 pg/ml, respectively. We did not find any statistically significant correlation between circulating PD-L1 and tissue expression of PD-L1/PD-1. Some mild degree of positive correlation was determined between tissue PD-L1 and SUV<sub>max</sub> (ρ =&thinsp;0.390; p =&thinsp;0.0148). Hierarchical clustering combining circulating, tissue, and metabolic parameters identified clusters with high metabolic tumor burden or high expression of plasma PD-L1 levels (Z score ≥ 2) as having a poor DFS (p =&thinsp;0.033). The multivariate analysis detected stage and metabolism (i.e., SUV<sub>max</sub> and SUV<sub>peak</sub>) as independent prognostic factors for DFS.</p> <p>CONCLUSION:</p> <p>Plasma levels of PD-L1 are independent of the expression of PD-1/PD-L1 in NSCLC tumor tissue and, when combined with other clinical-pathological parameters, allow for the identification of clusters with different outcomes.</p>
Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"
<p>This record contains raw data related to article “Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"</p> <p><strong>Introduction: </strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients.</p> <p><strong>Materials and methods: </strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS.</p> <p><strong>Results: </strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI ≤ 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI > 48 months (3-year OS 73.5%).</p> <p><strong>Conclusions: </strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.</p>
Dataset related to article "Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors"
<p>This record contains raw data related to article “Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors"</p> <p><strong>Introduction: </strong> In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI).</p> <p><strong>Methods: </strong> Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response assessment after 6-8 weeks. Patients who received ATB within 1 month before or after the first dose of ICI were compared with those who did not. Response assessment according to iRECIST and EORTC was evaluated, as well as progression-free survival (PFS) and overall survival (OS). For semi-quantitative parameters, we computed metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their variations (∆).</p> <p><strong>Results: </strong> Twenty NSCLC cases of 50 (40%) had received ATB. Patients receiving ATB had a higher number of metastases (<em>p</em> = 0.046), and were associated with an elevated tumor burden, expressed by TLG (687 vs. 235.3, <em>p</em> = 0.007) and MTV (125.6 vs. 40.6, <em>p</em> = 0.002), compared to no-ATB patients. According to iRECIST, progressive disease rate was significantly higher for ATB group (64.7% vs. 27.6%, <em>p</em> = 0.029). Likewise, PFS was shorter for ATB compared to no-ATB (median 4.1 vs. 12.4 months, <em>p</em> = 0.004), while no difference for OS was detected. On multivariate analysis, the effect of ATB remained significant for poor PFS along with performance status (ECOG ≥ 1), and ∆SUVmax.</p> <p><strong>Conclusions: </strong> ATB therapy seems to be associated with a worse treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with ICI.</p>
Dataset related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy "
<p>This record contains raw data related to article “Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy"</p> <p>Abstract:</p> <p><strong>Background: </strong> This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC).</p> <p><strong>Methods: </strong> We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50-60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors.</p> <p><strong>Results: </strong> Between 2011 and 2019, 210 patients were treated, 113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression. The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (<em>p</em> = 0.001) and LC (<em>p</em> = 0.005). Acute and late toxicity occurred in 82% and 26% of patients.</p> <p><strong>Conclusions: </strong> Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.</p>
Dataset related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy"
<p>This record contains data related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy"</p> <p>Background: This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC).</p> <p>Methods: We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50–60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors.</p> <p>Results: Between 2011 and 2019, 210 patients were treated,113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression.<br> The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (p = 0.001) and LC (p = 0.005). Acute and late toxicity occurred in 82% and 26% of patients.</p> <p>Conclusions: Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.</p>
Dataset related to: "Perceptual and qualitative voice alterations detected by GIRBAS in patients with Parkinson's disease: is there a relation with lung function and oxygenation?"
<p>We provide the raw data used for the following article:</p> <p>Olivares A, Comini L, Di Pietro DA, Vezzadini G, Luisa A, Boccali E, Boccola S, Vitacca M. <strong>Perceptual and qualitative voice alterations detected by GIRBAS in patients with Parkinson's disease: is there a relation with lung function and oxygenation?</strong> Aging Clin Exp Res. 2023 Mar;35(3):633-638. doi: 10.1007/s40520-022-02324-4. </p> <p>Abstract</p> <p><strong>Background: </strong>Impairments in respiration, voice and speech are common in people with Parkinson's disease (PD).</p> <p><strong>Aims: </strong>To evaluate the prevalence of dysphonia, assessed by a specific acoustic evaluation and description of the voice by the speech therapist (GIRBAS), and its relation with lung function and oxygenation, in particular cough ability and during the night or exercise desaturation.</p> <p><strong>Methods: </strong>This is a posthoc analysis of a prospective cross-sectional observational study on PD patients collecting anthropometric and clinical data, comorbidities, PD severity, motor function and balance, respiratory function at rest, during exercise and at night, voice function with acoustic analysis and presence of speech disorders, in addition to the GIRBAS scale. Based on GIRBAS Global dysphonia ('G') score, we divided patients into dysphonic (moderate-to-severe deviance from the euphonic condition) vs. no/mild dysphonic and analyzed the relations with respiratory impairments.</p> <p><strong>Results: </strong>We analyzed 55 patients and found significant impairments in both respiratory and voice/speech functions. Most patients (85.5%) presented mild-to-severe deviance from the euphonic condition in at least one GIRBAS perceptual element (80% of cases for Global dysphonia) and only 14.5% did not show deviance in all elements simultaneously. At Odds Ratio analysis, the risk of presenting nocturnal desaturation and reduced peak cough expiratory flow was approximately 24 and 8 times higher, respectively, in dysphonic patients vs. those with no/mild dysphonia.</p> <p><strong>Conclusion: </strong>Perceptual and qualitative evaluation of the voice with GIRBAS showed that mild-to-severe dysphonia was highly prevalent in PD patients, and associated with nocturnal oxygen desaturation and poor cough ability.</p>
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
ClinicalTrials.gov study NCT01449357. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
ClinicalTrials.gov study NCT04504513. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung
ClinicalTrials.gov study NCT04507919. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.